Evidence map›Paper›PMID 27729184›Full record

ArticleJournal of diabetes and its complications2017

Deficiency of the complement regulatory protein CD59 accelerates the development of diabetes-induced atherosclerosis in mice.

Fengming Liu, Rupam Sahoo, Xiaowen Ge, Lin Wu, Pamela Ghosh, Xuebin Qin, Jose A Halperin

Open access · greenAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of diabetes and its complications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Platelets and Complement Cross-Talk in Early Atherogenesis.Frontiers in cardiovascular medicine · 2019
    Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Fengming LiuDivision of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Rupam SahooDivision of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Xiaowen GeDivision of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Lin WuDivision of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Pamela GhoshDivision of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Xuebin QinDivision of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Jose A HalperinDivision of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: jhalperin@partners.org.
Harvard University · USBrigham and Women's Hospital · US

Funding

Human Studies on Blood Levels of Glycated CD59 as a Biomarker in DiabetesR01DK101442 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI HALPERIN, JOSE A · 2014 to 2018
$3.5M
Complement in the Vascular Complications of DiabetesR01DK062994 · NIDDK · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI HALPERIN, JOSE A · 2002 to 2005
$2.8M
Development of Therapeutic CD59 inhibitor for treating B-cell malignanciesR01CA166144 · NCI · TEMPLE UNIV OF THE COMMONWEALTH · PI QIN, XUEBIN · 2013 to 2017
$1.7M
Glycation inactivation of human CD59 and diabetic complicationsR01HL107762 · NHLBI · HARVARD MEDICAL SCHOOL · PI HALPERIN, JOSE A · 2012 to 2015
$1.6M
Role of Complement in Vascular Diabetic ComplicationsR01DK060979 · NIDDK · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI HALPERIN, JOSE A · 2002 to 2005
$1.4M
NCI NIH HHS R01 CA166144NHLBI NIH HHS R01 HL107762NIDDK NIH HHS R01 DK060979NIDDK NIH HHS R01 DK062994NIDDK NIH HHS R01 DK101442
6 · The paper itself

Abstract

aimsClinical and experimental evidence supports a strong link between the complement system, complement regulatory proteins and the pathogenesis of diabetes vascular complications. We previously reported that the complement regulatory protein CD59 is inactivated by glycation in humans with diabetes. Our objective for this study is to assess experimentally how the deficiency of CD59 impacts the development of diabetic atherosclerosis in vivo.

methodsWe crossed mCD59 sufficient and deficient mice into the ApoE

resultsDiabetic mCD59 deficient (mCD59ab

conclusionsThe deficiency of CD59 accelerates the development of diabetic atherosclerosis.

Indexed as

AnimalsAortaApolipoproteins EAtherosclerosisBlood GlucoseCD59 AntigensComplement ActivationComplement Membrane Attack ComplexCrosses, GeneticDiabetes Mellitus, Type 1Diabetic AngiopathiesEndothelium, VascularLipid MetabolismMacrophage ActivationMice, Inbred C57BLMice, KnockoutApolipoproteins EBlood GlucoseCD59 AntigensCD59a protein, mouseCD59b protein, mouseComplement Membrane Attack ComplexStreptozocinAtherosclerosisCD59ComplementDiabetesDiabetic vascular complicationsMembrane attack complex

Identifiers

PMID27729184
PMCPMC5460985
OpenAlexW2510576236

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.